<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20100331103512+02'00'</creation_date><modification_date>D:20100331103514+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-99-100_h_dec_13.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header></section><section><header>en  
   en</header><p>european commission brussels, 23.3.2010 c(2010)2000</p></section><section><header>commission decision of 23.3.2010 
 amending the marketing authorisation for &quot;cetrotide - cetrorelix (as acetate)&quot;, a 
 medicinal product for human use, granted by decision c(1999)939 
 (only the english text is authentic)</header></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission decision of 23.3.2010 
 amending the marketing authorisation for &quot;cetrotide - cetrorelix (as acetate)&quot;, a 
 medicinal product for human use, granted by decision c(1999)939 
 (text with eea relevance)</header><p>the european commission, having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, and in particular article 10(2) thereof, having regard to commission regulation (ec) no 1085/2003 of 3 june 2003 concerning 
 the examination of variations to the terms of a marketing authorisation for medicinal 
 products for human use and veterinary medicinal products falling within the scope of 
 council regulation (eec) no 2309/93
 2, and in particular the third subparagraph of article 4(5) thereof, 
 having regard to the notifications submitted by serono europe limited under 
 article 4(1) of regulation (ec) no 1085/2003, 
 having regard to directive 2001/83/ec of the european parliament and of the council of 
 6 november 2001 on the community code relating to medicinal products for human use
 3, and in particular article 61(3) thereof, 
 whereas: 
 (1)</p><p>the european medicines agency acknowledged, between 13 july 2009 and 13 
 january 2010, the validity of the notification(s) for minor variations of type ia, 
 informing the marketing authorisation holder accordingly, and has prepared a list 
 of the notification(s). the variation(s) took effect from the date of the 
 communication from the european medicines agency concerning the validation. 
 (2)</p><p>serono europe limited submitted, under article 61(3) of directive 
 2001/83/ec, a notification(s) for changes to an aspect of the labelling or the 
 package leaflet, which has (have) not yet been included in decision c(1999)939 
 of 13 april 1999. 
 (3)</p><p>the marketing authorisation should be updated, and decision c(1999)939 of 13 
 april 1999 amended accordingly.</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 159, 27.6.2003, p. 24. 3 oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>(4) for the sake of clarity and transparency, it is advisable, following the amendment 
 of part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c(1999)939 should therefore be replaced, 
 has adopted this decision: 
 article 1 decision c(1999)939 is amended as follows: 1) the following list of notifications for minor variations is added to the updated 
 marketing authorisation. 
 application number 
 scope (eu numbers affected) 
 emea/h/c/233/ia/31 
 1 (ia) (eu/1/99/100/001-003)</p><p>
 2) the following list of notifications for changes to an aspect of the labelling or the 
 package leaflet is added to the updated marketing authorisation; 
 application number 
 annex (eu numbers affected) 
 emea/h/c/233/n/32 
 iiib (eu/1/99/100/001-003)</p><p>
 3) annex i is replaced by the text set out in annex i to this decision; 
 4) annex iii is replaced by the text set out in annex iii to this decision. 
 article 2 this decision is addressed to serono europe limited, 56, marsh wall, london e14 9tp, united kingdom. 
 done at brussels, 23.3.2010.</p><p>for the commission</p><p>
 robert madelin</p><p>
 director-general</p></section></body></xml>